Department of Cardiovascular Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Am J Cardiol. 2014 Aug 15;114(4):555-61. doi: 10.1016/j.amjcard.2014.05.034. Epub 2014 Jun 6.
Ischemic heart disease is a major risk factor for morbidity and mortality in patients with end-stage renal disease. However, long-term benefits of percutaneous coronary intervention (PCI) relative to coronary artery bypass grafting (CABG) in those patients is still unclear in the drug-eluting stent era. We identified 388 patients with multivessel and/or left main disease with end-stage renal disease requiring dialysis among 15,939 patients undergoing first coronary revascularization enrolled in the Coronary REvascularization Demonstrating Outcome Study in Kyoto PCI/CABG Registry Cohort-2 (PCI: 258 patients and CABG: 130 patients). The CABG group included more patients with 3-vessel (38% vs 57%, p <0.001) and left main disease (10% vs 34%, p <0.001). Preprocedural Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery score in the CABG group was significantly higher than that in the PCI group (23.5 ± 8.7 vs 29.4 ± 11.0, p <0.001). Unadjusted 30-day mortality was 2.7% for PCI and 5.4% for CABG. Cumulative 5-year all-cause mortality was 52.3% for PCI and 49.9% for CABG. Propensity score-adjusted all-cause mortality was not different between PCI and CABG (hazard ratio [HR] 1.33, 95% confidence interval [CI] 0.85 to 2.09, p = 0.219). However, the excess risk of PCI relative to CABG for cardiac death was significant (HR 2.10, 95% CI 1.11 to 3.96, p = 0.02). The risk of sudden death was also higher after PCI (HR 4.83, 95% CI 1.01 to 23.08, p = 0.049). The risk of myocardial infarction after PCI tended to be higher than after CABG (HR 3.30, 95% CI 0.72 to 15.09, p = 0.12). The risk of any coronary revascularization after PCI was markedly higher after CABG (HR 3.78, 95% CI 1.91 to 7.50, p <0.001). Among the 201 patients who died during the follow-up, 94 patients (47%) died from noncardiac morbidities such as stroke, respiratory failure, and renal failure. In patients with multivessel and/or left main disease undergoing dialysis, 5-year outcomes revealed that CABG relative to PCI reduced the risk of cardiac death, sudden death, myocardial infarction, and any revascularization. However, the risk of all-cause death was not different between PCI and CABG.
缺血性心脏病是终末期肾病患者发病率和死亡率的主要危险因素。然而,在药物洗脱支架时代,经皮冠状动脉介入治疗(PCI)相对于冠状动脉旁路移植术(CABG)在这些患者中的长期获益仍不清楚。我们在京都经皮冠状动脉血运重建研究中的 15939 例首次冠状动脉血运重建患者中确定了 388 例需要透析的多支血管和/或左主干疾病的终末期肾病患者,这些患者来自冠状动脉血运重建研究中的多血管和/或左主干疾病患者(PCI:258 例,CABG:130 例)。CABG 组包括更多的 3 支血管(38% vs. 57%,p<0.001)和左主干疾病(10% vs. 34%,p<0.001)患者。CABG 组的术前血管重建治疗与心脏手术联合评分(Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery score)明显高于 PCI 组(23.5±8.7 vs. 29.4±11.0,p<0.001)。未经调整的 30 天死亡率为 PCI 组 2.7%,CABG 组 5.4%。未经调整的 5 年全因死亡率为 PCI 组 52.3%,CABG 组 49.9%。经倾向评分调整后,PCI 和 CABG 之间的全因死亡率无差异(风险比[HR]1.33,95%置信区间[CI]0.85 至 2.09,p=0.219)。然而,与 CABG 相比,PCI 治疗导致心脏死亡的风险显著升高(HR 2.10,95%CI 1.11 至 3.96,p=0.02)。PCI 后心脏性猝死的风险也更高(HR 4.83,95%CI 1.01 至 23.08,p=0.049)。与 CABG 相比,PCI 后心肌梗死的风险也有升高趋势(HR 3.30,95%CI 0.72 至 15.09,p=0.12)。与 CABG 相比,PCI 后任何冠状动脉血运重建的风险明显更高(HR 3.78,95%CI 1.91 至 7.50,p<0.001)。在随访期间死亡的 201 例患者中,94 例(47%)死于非心脏性并发症,如中风、呼吸衰竭和肾衰竭。在接受透析的多支血管和/或左主干疾病患者中,5 年结果显示,与 PCI 相比,CABG 可降低心脏死亡、心脏性猝死、心肌梗死和任何血运重建的风险。然而,PCI 和 CABG 之间的全因死亡风险无差异。